196 related articles for article (PubMed ID: 21673386)
21. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice.
Taheri A; Dinarvand R; Ahadi F; Khorramizadeh MR; Atyabi F
Int J Pharm; 2012 Jul; 431(1-2):183-9. PubMed ID: 22531853
[TBL] [Abstract][Full Text] [Related]
22. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
Steinhauser IM; Langer K; Strebhardt KM; Spänkuch B
Biomaterials; 2008 Oct; 29(29):4022-8. PubMed ID: 18653231
[TBL] [Abstract][Full Text] [Related]
23. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
24. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation.
Wacker M; Zensi A; Kufleitner J; Ruff A; Schütz J; Stockburger T; Marstaller T; Vogel V
Int J Pharm; 2011 Jul; 414(1-2):225-32. PubMed ID: 21571055
[TBL] [Abstract][Full Text] [Related]
25. Probing the interaction of human serum albumin with ciprofloxacin in the presence of silver nanoparticles of three sizes: multispectroscopic and ζ potential investigation.
Iranfar H; Rajabi O; Salari R; Chamani J
J Phys Chem B; 2012 Feb; 116(6):1951-64. PubMed ID: 22224861
[TBL] [Abstract][Full Text] [Related]
26. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.
Dreis S; Rothweiler F; Michaelis M; Cinatl J; Kreuter J; Langer K
Int J Pharm; 2007 Aug; 341(1-2):207-14. PubMed ID: 17478065
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy.
Oh KS; Song JY; Cho SH; Lee BS; Kim SY; Kim K; Jeon H; Kwon IC; Yuk SH
J Control Release; 2010 Dec; 148(3):344-50. PubMed ID: 20797418
[TBL] [Abstract][Full Text] [Related]
28. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
Altintas I; Heukers R; van der Meel R; Lacombe M; Amidi M; van Bergen En Henegouwen PM; Hennink WE; Schiffelers RM; Kok RJ
J Control Release; 2013 Jan; 165(2):110-8. PubMed ID: 23159529
[TBL] [Abstract][Full Text] [Related]
29. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
Talekar M; Kendall J; Denny W; Garg S
Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
[TBL] [Abstract][Full Text] [Related]
30. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.
Zhang Z; Chen J; Ding L; Jin H; Lovell JF; Corbin IR; Cao W; Lo PC; Yang M; Tsao MS; Luo Q; Zheng G
Small; 2010 Feb; 6(3):430-7. PubMed ID: 19957284
[TBL] [Abstract][Full Text] [Related]
31. Characterization and side effect analysis of a newly designed nanoemulsion targeting human serum albumin for drug delivery.
Divsalar A; Saboury AA; Nabiuni M; Zare Z; Kefayati ME; Seyedarabi A
Colloids Surf B Biointerfaces; 2012 Oct; 98():80-4. PubMed ID: 22659208
[TBL] [Abstract][Full Text] [Related]
32. Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems.
Chen K; Wacker M; Hackbarth S; Ludwig C; Langer K; Röder B
J Photochem Photobiol B; 2010 Dec; 101(3):340-7. PubMed ID: 20813540
[TBL] [Abstract][Full Text] [Related]
33. Water soluble nanoporous nanoparticle for in vivo targeted drug delivery and controlled release in B cells tumor context.
De Angelis F; Pujia A; Falcone C; Iaccino E; Palmieri C; Liberale C; Mecarini F; Candeloro P; Luberto L; de Laurentiis A; Das G; Scala G; Di Fabrizio E
Nanoscale; 2010 Oct; 2(10):2230-6. PubMed ID: 20835434
[TBL] [Abstract][Full Text] [Related]
34. Molecular dynamics simulation and binding studies of beta-sitosterol with human serum albumin and its biological relevance.
Sudhamalla B; Gokara M; Ahalawat N; Amooru DG; Subramanyam R
J Phys Chem B; 2010 Jul; 114(27):9054-62. PubMed ID: 20565066
[TBL] [Abstract][Full Text] [Related]
35. Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles.
Kouchakzadeh H; Shojaosadati SA; Tahmasebi F; Shokri F
Int J Pharm; 2013 Apr; 447(1-2):62-9. PubMed ID: 23454849
[TBL] [Abstract][Full Text] [Related]
36. Uniformity of drug payload and its effect on stability of solid lipid nanoparticles containing an ester prodrug.
Kim JK; Howard MD; Dziubla TD; Rinehart JJ; Jay M; Lu X
ACS Nano; 2011 Jan; 5(1):209-16. PubMed ID: 21158414
[TBL] [Abstract][Full Text] [Related]
37. Redox responsive curcumin-loaded human serum albumin nanoparticles: Preparation, characterization and in vitro evaluation.
Saleh T; Soudi T; Shojaosadati SA
Int J Biol Macromol; 2018 Jul; 114():759-766. PubMed ID: 29567499
[TBL] [Abstract][Full Text] [Related]
38. Cooperative dual-stimuli-triggered aggregation of poly-L-histidine-functionalized au nanoparticles.
Guan J; Li J; Guo Y; Yang W
Langmuir; 2009 Mar; 25(5):2679-83. PubMed ID: 19437690
[TBL] [Abstract][Full Text] [Related]
39. Effect of molecular weight on the oleoyl-chitosan nanoparticles as carriers for doxorubicin.
Zhang J; Chen XG; Sun GZ; Huang L; Cheng XJ
Colloids Surf B Biointerfaces; 2010 Jun; 77(2):125-30. PubMed ID: 20172698
[TBL] [Abstract][Full Text] [Related]
40. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB).
Ulbrich K; Hekmatara T; Herbert E; Kreuter J
Eur J Pharm Biopharm; 2009 Feb; 71(2):251-6. PubMed ID: 18805484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
